Verve Therapeutics experienced a significant 23% increase in its stock price during premarket trading on Monday. This jump followed the announcement of successful early-stage trial results for their gene editing therapy, VERVE-102. The therapy demonstrated dose-dependent therapeutic effects in patients suffering from high cholesterol. These promising outcomes highlight the potential impact of VERVE-102 on future treatments for high cholesterol.
Biotech2k
@Biotech2k1
·
2h I don’t think these numbers are good enough for $VERV to be competitive in this space.https://ir.vervetx.com/news-releases/news-release-details/verve-therapeutics-announces-positive-initial-data-heart-2-phase…
RazorSharpDNA
@RazorSharpDNA
·
Apr 11 Out of all the promising CRISPR/Gene Editing (Base, Prime, etc) companies I’ve invested in or traded over the years, I haven’t owned $VERV until now. I recall almost investing back in 2023, but then they had a set back with safety data readouts in Nov 2023 which now appear more
BiotechTV
@BiotechTVHQ
·
2h 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After switching to a new GalNAc-LNP delivery vehicle a year ago,
@VerveTx
today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO
@skathire
covers the data. $VERVFull video: https://biotechtv.com/post/verve-therapeutics-april-14-2025…
stefan katafai
@SKatafai
·
55m Verve Therapeutics ( $VERV)
$3.26 +0.21 (+6.89%)
$4.03 +0.77 (+23.62%)VERVE-102
One shot lowers bad cholesterol (LDL-C) by editing the PCSK9 gene
For HeFH or early CAD, it cut LDL-C 53% (up to 69%) in 14 patients, with 59% drops at higher doses . Safe, no major issues
malinvestment.jpeg
@malinvested
·
1h VERV-102: gene editing delivered by LNP which contains mRNA expressing an adenine base editor and gRNAthe sort of therapy that if it progresses could make $MRVI
Sek Kathiresan MD
@skathire
·
3h @VerveTx
team is thrilled today to present initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, an in vivo base editing investigational medicine targeting PCSK9And the emerging product profile of VERVE-102 (for patients receiving ≥50mg total RNA dose):a. A
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
